ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 13 2024 - 5:00AM
Garching / Munich,
Germany, December 13, 2024 – ITM
Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical
biotech company, today announced that its Chief Executive Officer,
Dr. Andrew Cavey and Chief Financial Officer, Dr. Klaus Maleck will
participate in the 43rd Annual J.P. Morgan Healthcare Conference in
San Francisco. Dr. Andrew Cavey will present a corporate overview
on Monday, January 13, 2025, at 11:30 am PST in the Mission Bay
Room (32nd Floor) at The Westin St. Francis.
For further information, please contact:
Investor RelationsBen OrzelekPhone: +49 89 329
8986 1009Email: investors@itm-radiopharma.com
Corporate CommunicationsKathleen Noonan / Julia
WestermeirPhone: +49 89 329 8986 1500Email:
communications@itm-radiopharma.com
ITM Isotope Technologies Munich
SEITM, a leading radiopharmaceutical biotech company, is
dedicated to providing a new generation of radiomolecular precision
therapeutics and diagnostics for hard-to-treat tumors. We aim to
meet the needs of cancer patients, clinicians and our partners
through excellence in development, production and global supply.
With improved patient benefit as the driving principle for all we
do, ITM advances a broad precision oncology pipeline, including
multiple phase III studies, combining the company’s high-quality
radioisotopes with a range of targeting molecules. By leveraging
our two decades of pioneering radiopharma expertise, central
industry position and established global network, ITM strives to
provide patients with more effective targeted treatment to improve
clinical outcome and quality of life. www.itm-radiopharma.com
- ITM to Present at the 43rd Annual J.P. Morgan Healthcare
Conference